Healthcare Services M&A
Healthcare M&A is one of the most active and specialist-dominated advisory markets in the country. In 2025, PwC counted approximately 910 health services transactions. Patient Square Capital’s $2.6 billion acquisition of Premier Inc., Bain Capital’s $2.6 billion acquisition of HealthEdge, Cencora’s acquisition of Retina Consultants of America, and TPG/AmerisourceBergen’s OneOncology deal (structured with a 19x EBITDA put-call) define the top of the market. Private equity drives more than 90% of physician practice transactions.
Parkland Capital Partners is a lower middle market M&A advisory firm with deep sector focus across real estate services, industrial services, business services, and infrastructure services. Our healthcare practice is narrowly focused on healthcare-adjacent services businesses that intersect with our core sector strengths: healthcare facility services, healthcare real estate services, healthcare construction and engineering services, healthcare logistics and distribution, and healthcare-adjacent business services (RCM, staffing, consulting, administrative services).
If you are operating a healthcare-adjacent services business generating $1M+ in EBITDA and thinking about a transaction in the next 12 to 24 months, this page is for you.
For healthcare-adjacent services businesses specifically, the 2026 M&A environment is unusually favorable. The broader healthcare M&A recalibration over the past 18 months has sharpened buyer focus on exactly the categories where Parkland is positioned to help.
Private equity capital has shifted materially away from direct provider reimbursement exposure and toward tech-enabled services, operational support services, and specialty infrastructure services that support healthcare delivery without carrying direct reimbursement or regulatory risk. PwC’s 2026 health services outlook noted that investors are continuing to “shift away from reimbursement and regulatory exposure and toward software and services platforms that support care delivery.” That shift flows directly to healthcare RCM, healthcare staffing, healthcare IT services, healthcare consulting, healthcare facility services, healthcare logistics, and related healthcare-adjacent services categories.
Health systems and diversified healthcare companies continue to offload non-core services assets as they concentrate balance sheet capacity on core clinical and care delivery operations. PwC reported that health systems will continue “offloading noncore assets like labs, home health and revenue cycle units as they seek liquidity and strategic focus.” These divestitures create a steady supply of services businesses entering the lower middle market transaction ecosystem.
California and Oregon enacted legislation in 2024 and 2025 limiting private equity influence on healthcare provider decision-making. This regulatory trajectory has materially accelerated PE migration away from direct provider roll-ups and toward the services layer that supports healthcare delivery without triggering corporate practice of medicine or similar regulatory concerns. The operational services, facility services, real estate services, construction services, and business services businesses that support healthcare delivery are becoming meaningfully more attractive targets on a relative basis.
Specific end-market demand drivers remain historic in their strength. Aging demographics continue to expand healthcare capital demand. Hospital and ASC construction activity remains elevated. Medical office building development is active in most major markets. Life sciences facility construction and engineering demand continues to grow. Data center-driven healthcare IT infrastructure is scaling aggressively. Each creates direct opportunity for the healthcare-adjacent services businesses Parkland works with.
Healthcare-adjacent services multiples have meaningful spread based on healthcare end-market exposure, regulatory sophistication, and contract quality. The ranges below are directional benchmarks for how credible buyers approach healthcare-adjacent services valuation in 2026. These are ranges for services businesses adjacent to healthcare, not for healthcare provider businesses themselves (which are priced differently and should be addressed with specialist healthcare advisors).
Sub-category and healthcare end-market concentration drive meaningful multiple variation. Four illustrative examples:
Healthcare facility services. Cleaning, maintenance, security, engineering for hospitals, ASCs, MOBs, and life sciences facilities. Premium category given recurring contract characteristics and regulatory barriers to entry. ABM’s acquisition of WGNSTAR in February 2026 reflected the premium that scaled facility services acquirers pay for specialty capabilities in regulated technical environments, and healthcare facility services follows a similar logic.
Healthcare construction management and engineering services. Premium category given healthcare facility construction tailwinds, life sciences facility demand, and the regulatory complexity embedded in healthcare construction project delivery. GHK Capital Partners’ acquisition of CPL in February 2026 reflected the premium paid for AEC firms with healthcare end-market focus.
Healthcare logistics, distribution, and supply chain services. Premium category given the regulatory complexity of pharmaceutical logistics, medical device distribution, and specialty healthcare supply chain operations. Cold chain and temperature-controlled healthcare logistics command particular premiums.
Healthcare-adjacent business services (RCM, staffing, consulting, administrative, IT services). Varied multiples depending on the degree of direct reimbursement exposure, compliance sophistication, and AI integration. Tech-enabled RCM bolt-ons are among the hottest areas in current healthcare M&A per PwC’s 2026 outlook.
Five factors move the multiple more than anything else. First, healthcare end-market concentration — businesses with strong hospital system, ASC, life sciences, or specialty healthcare customer concentration command premiums over generalist services businesses with incidental healthcare exposure. Second, contract structure — multi-year GPO contracts, hospital system MSAs, and long-term services agreements command premiums over transactional revenue. Third, compliance and regulatory sophistication — documented HIPAA compliance, Joint Commission familiarity, accreditation support experience, and healthcare-specific licensing command premiums. Fourth, management depth and healthcare operational knowledge. Fifth, the absence of direct reimbursement exposure — buyers increasingly discount businesses with revenue tied directly to Medicare or Medicaid reimbursement rates given regulatory volatility.
For healthcare-adjacent services businesses specifically, the case against generalist brokers is sharp. Healthcare-adjacent services do not trade like generic services businesses. The drivers of value are healthcare customer concentration and contract structure, regulatory and compliance sophistication (HIPAA, healthcare-specific licensing, facility accreditations like Joint Commission), specialty technical capabilities relevant to healthcare end markets, the depth of healthcare-specific operational knowledge embedded in the management team, and the sophistication of systems built for healthcare customers’ specific requirements. Generalist brokers miss most of this.
The confidentiality problem is just as serious. Many brokers list healthcare-adjacent services businesses on BizBuySell or similar marketplaces, post teasers to broker networks, or run open auctions that expose the business to buyers with no real capacity to close. In healthcare-adjacent services, that leak reaches clinical customers, healthcare system procurement officers, facility management teams, and competing services providers within days. Healthcare customers often maintain rigorous vendor credentialing processes that create real sensitivity around ownership changes. A leak during a sale process can directly trigger vendor recertification reviews, RFP processes on upcoming contracts, and competitive poaching of key account managers before any deal closes.
The right advisor for a healthcare-adjacent services business is one who understands the intersection of services business economics, healthcare end-market dynamics and knows which services-focused PE platforms, industrial services consolidators, and healthcare services sponsors are paying premium multiples today for which sub-verticals.
Ridgemont Equity Partners, Lindsay Goldberg, Audax, Genstar Capital, The Jordan Company, Wind Point Partners, Greenbriar Equity, Court Square Capital, Pfingsten Partners, Platinum Equity, Harvest Partners, and the broader services-focused PE universe are active acquirers of healthcare-adjacent services businesses with durable cash flows and low reimbursement risk. These sponsors typically pay premium multiples for businesses that fit their broader services thesis without healthcare regulatory complexity.
ABM Industries (healthcare facility services), Aramark (healthcare food and facility services), Sodexo Healthcare, Compass Group Healthcare (Morrison Healthcare), Crothall Healthcare, Medxcel, and similar scaled healthcare-adjacent services operators are acquiring specialty businesses to extend scale, geographic reach, and sub-vertical capabilities.
Specialty healthcare sponsors whose mandates extend into healthcare-adjacent services (RCM, staffing, administrative services, supply chain). These sponsors blend healthcare sector fluency with services-business underwriting and can be particularly aggressive bidders for the right targets.
PE-backed industrial services and infrastructure services platforms increasingly acquire healthcare-adjacent specialty trades, facility services, and engineering services to add premium end-market concentration to existing platforms. This buyer category is often underestimated by founders and generalist brokers but can be the highest-paying segment for the right targets.
Opportunistic capital looking for well-run founder-led healthcare-adjacent services businesses with clear operational upside. Often move faster than institutional sponsors and offer structural flexibility, though with smaller dry powder and tighter financing dependencies.
Healthcare M&A is a specialist-dominated category. If you are operating a physician practice, MSO, ambulatory surgery center, behavioral health platform, hospital, medical device company, pharmaceutical services business, biotech company, diagnostic imaging center, specialty pharmacy, healthcare IT platform, digital health business, or any other traditional healthcare provider or regulated healthcare operator, you should engage a specialist healthcare M&A advisor.
The specialist universe is deep and genuinely earned its position. Provident Healthcare Partners, Edge Healthcare Partners, FOCUS Investment Banking, Physician Growth Partners, VMG Health, Cain Brothers (KeyBanc Capital Markets), and Ziegler (senior care specialist) lead the lower middle market. Houlihan Lokey Healthcare, Jefferies Healthcare, Leerink Partners, Piper Sandler Healthcare, TD Cowen Healthcare, Raymond James Healthcare, Lazard Healthcare, Evercore Healthcare, Brentwood Capital, and the healthcare teams at Morgan Stanley, Goldman Sachs, and JPMorgan handle the middle market and above. Each has dedicated healthcare sector teams, proprietary physician practice pricing databases, relationships with every active healthcare PE sponsor, and the regulatory fluency required to navigate reimbursement, corporate practice of medicine, Stark/Anti-Kickback, HIPAA, and state-specific healthcare regulation. We openly recommend them for traditional healthcare provider and regulated healthcare transactions.
Parkland’s healthcare practice is narrow by design. We work with founder-led healthcare-adjacent services businesses whose operational DNA, buyer universe, and value drivers look more like the services businesses in our core sectors than like traditional healthcare providers. These businesses typically trade to PE-backed services platforms, industrial services consolidators, real estate services consolidators, or business services sponsors rather than to dedicated healthcare PE firms. The buyer universe Parkland covers every day is exactly the buyer universe these businesses need to reach.
If you are uncertain which category your business falls into, that is a conversation worth having in the first call. We will tell you honestly which advisor profile is the right fit for your specific business.
Most of the value in a healthcare-adjacent services sale is made in the year before the teaser goes out. Repositioning healthcare end-market mix toward high-multiple categories (hospital systems, ASCs, life sciences, specialty healthcare), strengthening contract portfolio quality and durability, documenting healthcare-specific compliance systems (HIPAA, accreditation support, licensing), developing management depth below the founder, and cleaning up 36 months of normalized financials can each add tens of percent to the final sale price.
The reverse is also true. Going to market with messy financials, undocumented compliance systems, heavy customer concentration, thin management depth, or unresolved compliance issues leaves value on the table that no process can recover. Earnouts and performance-based consideration are common in healthcare-adjacent services transactions and typically tie a meaningful portion of the purchase price to post-close performance, customer retention, and compliance continuity over 12 to 24 months. A messy book exposes the seller to real earnout risk. A clean book on strong systems reduces it materially.
We work with founders well before the official engagement, sometimes for a year or more, to position the business for the outcome they actually want.
You do not get handed off to an analyst once the engagement letter is signed. The person you meet on the first call is the person negotiating your LOI.
We do not post businesses on public marketplaces, blast teasers to buyer aggregator lists, or run open online auctions. Every outreach is direct, curated, and tailored to your specific business. Confidentiality is protected at every stage.
We do not recycle. For each mandate, we construct a buyer universe tailored to your specific sub-vertical, scale, healthcare end-market exposure, and strategic fit, drawing on our proprietary database, active coverage relationships, and direct conversations with the services-focused sponsors, healthcare-adjacent strategics, and specialty sponsor universes.
The goal is multiple credible bidders at LOI stage with real economic tension between them. That is what drives the final 10% to 20% of enterprise value that matters most. Competitive tension does not require a public auction. It requires the right buyers engaged in parallel, with the same information and the same deadline.
A high headline LOI that falls apart in diligence, or erodes materially through earnout mechanics and purchase price adjustments, is worth far less than the LOI number suggests. We vet bidders for real capability to close, negotiate earnout terms aggressively on behalf of sellers, and structure the process to keep the right buyers engaged through signing and funding.
Economics matter. They are not the only thing that matters.
The best outcomes we deliver for healthcare-adjacent services founders are the ones where the buyer honors the legacy of the business, takes care of the project managers, account managers, and operational teams who built it, and continues to serve the healthcare customers who trust the brand. Healthcare-adjacent services is a deeply relationship-driven business at every level. Healthcare customers contract with the business because of the reliability, compliance sophistication, and service quality it has built over years and decades of operating in a regulated environment. Healthcare customers are particularly sensitive to vendor ownership changes because vendor credentialing, compliance history, and operational continuity directly affect their own risk exposure. A high headline price from a buyer who cuts service capability, disrupts compliance systems, or breaks customer trust is not a win.
We spend real time on cultural fit. We vet buyers not just on financial capability and strategic rationale, but on how they have actually treated teams and customers they have acquired in the past. We talk to former sellers on the other side of acquisitions. We advise our clients on which bidders will be good stewards and which ones will not, even when the economics say otherwise.
We also believe the process itself should be as smooth as possible for founders who are running their businesses at the same time. Healthcare-adjacent services companies do not slow down for a sale. Contracts renew. Compliance audits happen. Customer calls come in. We run tight timelines, protect our clients’ calendars, manage diligence requests so they do not become a second full-time job, and stay selective on which buyers we bring to the table so that energy is spent on real bidders only.
We are a Dallas-based lower middle market M&A advisory firm with deep sector focus across real estate services, industrial services, business services, and infrastructure services. Dallas-Fort Worth is a major healthcare market anchored by UT Southwestern, Baylor Scott & White, Texas Health Resources, HCA, Medical City, and a deep ecosystem of ambulatory surgery centers, medical office buildings, and life sciences facilities. That concentration of healthcare infrastructure puts us in regular contact with the healthcare-adjacent services operators, sponsors, and strategic consolidators most actively transacting in the lower middle market today.
We work within the private equity middle market and strategic operator ecosystem, not as competitors to specialist healthcare investment banks or bulge-bracket healthcare M&A teams. For traditional healthcare provider and regulated healthcare transactions (physician practices, MSOs, ASCs, hospitals, behavioral health, medical devices, pharmaceutical services, biotech, healthcare IT platforms), we openly recommend that founders engage specialist healthcare advisors. Our lane is the healthcare-adjacent services businesses whose economics, buyer universe, and value drivers look more like the services businesses in our core sectors than like traditional healthcare providers.
Every mandate is run confidentially and bespoke to the business. We do not run open auctions, list companies on public marketplaces, or push teasers to aggregator networks. Information is shared only with named buyers we have vetted and qualified, under NDA, on a timeline we control.
The best time to engage an M&A advisor is 12 to 24 months before you intend to transact. The earliest conversations are about positioning, not process. What would a buyer pay for this business today? Where is the healthcare end-market exposure, contract quality, or compliance sophistication holding back the multiple? Which services-focused sponsors and healthcare-adjacent strategics should we be building relationships with now? What would it take to reach platform multiple territory in the next 24 months?
Those are the conversations that change outcomes. We offer complimentary initial consultations for healthcare-adjacent services founders generating at least $1M in EBITDA.
Significantly. The broader market trajectory is PE moving away from direct provider reimbursement exposure toward services businesses without reimbursement risk. For founders with businesses carrying meaningful Medicare or Medicaid reimbursement exposure, the buyer universe is increasingly healthcare-specialist PE firms rather than generalist services sponsors, and a specialist healthcare advisor is typically better positioned to reach the right buyer pool. For founders with predominantly commercial payor exposure or no direct reimbursement exposure at all, the generalist services buyer pool is often more competitive and Parkland may be well-positioned to run that process.
